Antibodies that bind zika virus envelope protein and uses thereof

Patent metadata

Field	Value
Publication number	US-11267873-B2
Application number	US-201716341845-A
Country	US
Kind code	B2
Filing date	Oct 13, 2017
Priority date	Oct 13, 2016
Publication date	Mar 8, 2022
Grant date	Mar 8, 2022

Abstract

Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

First claim

The invention claimed is:

1. An isolated monoclonal antibody, or antigen binding portion thereof, which binds to Zika virus envelope protein and comprises heavy and light chain variable regions, wherein the heavy and light chain amino acid sequences are selected from the group consisting of:
(a) SEQ ID NOs: 6 and 15, respectively;
(b) SEQ ID NOs: 6 and 5, respectively;
(c) SEQ ID NOs: 6 and 14, respectively;
(d) SEQ ID NOs: 6 and 16, respectively; and
(e) SEQ ID NOs: 6 and 17, respectively.

2. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , having neutralizing activity against Zika virus.

3. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, an IgD, and an IgE antibody.

4. The isolated monoclonal antibody, or antigen binding portion thereof, according to claim 3 , wherein the antibody is an IgG1 antibody.

5. A pharmaceutical composition comprising an isolated monoclonal antibody, or antigen binding portion thereof, of claim 1 , and a pharmaceutically acceptable carrier.

6. An isolated monoclonal antibody, or antigen binding portion thereof, which binds to Zika virus envelope protein and comprises heavy and light chain variable regions comprising the amino acid sequences of SEQ ID NOs: 6 and 15, respectively.

7. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 6 , having neutralizing activity against Zika virus.

8. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 6 , wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, an IgD, and an IgE antibody.

9. The isolated monoclonal antibody, or antigen binding portion thereof, according to claim 7 , wherein the antibody is an IgG1 antibody.

10. A pharmaceutical composition comprising an isolated monoclonal antibody or antigen binding portion thereof, of claim 6 , and a pharmaceutically acceptable carrier.

11. An isolated monoclonal antibody, or antigen binding portion thereof, which binds to Zika virus envelope protein and comprises heavy and light chain variable regions comprising the amino acid sequences of SEQ ID NOs: 6 and 5, respectively.

12. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 11 , having neutralizing activity against Zika virus.

13. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 11 , wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, an IgD, and an IgE antibody.

14. The isolated monoclonal antibody, or antigen binding portion thereof, according to claim 13 , wherein the antibody is an IgG1 antibody.

15. A pharmaceutical composition comprising an isolated monoclonal antibody or antigen binding portion thereof, of claim 11 , and a pharmaceutically acceptable carrier.

16. An isolated monoclonal antibody, or antigen binding portion thereof, which binds to Zika virus envelope protein and comprises heavy and light chain variable regions comprising the amino acid sequences of SEQ ID NOs: 6 and 14, respectively.

17. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 16 , having neutralizing activity against Zika virus.

18. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 16 , wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, an IgD, and an IgE antibody.

19. The isolated monoclonal antibody, or antigen binding portion thereof, according to claim P, wherein the antibody is an IgG1 antibody.

20. A pharmaceutical composition comprising an isolated monoclonal antibody or antigen binding portion thereof, of claim 16 , and a pharmaceutically acceptable carrier.

21. An isolated monoclonal antibody, or antigen binding portion thereof, which binds to Zika virus envelope protein and comprises heavy and light chain variable regions comprising the amino acid sequences of SEQ ID NOs: 6 and 16, respectively.

22. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 21 , having neutralizing activity against Zika virus.

23. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 21 , wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, an IgD, and an IgE antibody.

24. The isolated monoclonal antibody, or antigen binding portion thereof, according to claim 23 , wherein the antibody is an IgG1 antibody.

25. A pharmaceutical composition comprising an isolated monoclonal antibody or antigen binding portion thereof, of claim 21 , and a pharmaceutically acceptable carrier.

26. An isolated monoclonal antibody, or antigen binding portion thereof, which binds to Zika virus envelope protein and comprises heavy and light chain variable regions comprising the amino acid sequences of SEQ ID NOs: 6 and 17, respectively.

27. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 26 , having neutralizing activity against Zika virus.

28. The isolated monoclonal antibody, or antigen binding portion thereof, of claim 26 , wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, an IgD, and an IgE antibody.

29. The isolated monoclonal antibody, or antigen binding portion thereof, according to claim 28 , wherein the antibody is an IgG1 antibody.

30. A pharmaceutical composition comprising an isolated monoclonal antibody or antigen binding portion thereof, of claim 26 , and a pharmaceutically acceptable carrier.

Assignees

• Massachusetts Inst Technology
• Nat Univ Singapore

Inventors

• Sasisekharan Ram
• Tharakaraman Kannan
• Chan Kuan Rong
• Watanabe Satoru
• Vasudevan Subhash G
• Ooi Eng Eong

Classifications

• C07K16/116 Primary

  Togaviridae (F); Matonaviridae (F); Flaviviridae (F) · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C07K16/10

  RNA viruses · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• A61K2039/505

  comprising antibodies · CPC title